Guideline of integrated Chinese and western medicine for diagnosis and treatment of chronic obstructive pulmonary disease_Chinese Journal of Evidence-Based Medicine

Authors：

 Internal Medicine Committee of World Federation of Chinese Medicine Societies Chinese Medicine Societies

Corresponding author：

Internal Medicine Committee of World Federation of Chinese Medicine Societies Chinese Medicine Societies, Email: li_js8@163.com

Keywords：

Chronic obstructive pulmonary disease; Integrative medicine; Clinical practice guideline

DOI：

10.7507/1672-2531.202304016

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Chronic obstructive pulmonary disease (COPD), with high prevalence rate, mortality, and disability rate, and heavy burden caused by the disease, has become a major chronic disease seriously threatening public health worldwide. Chinese medicine and Western medicine both have advantages in diagnosing and treating COPD, which have been widely used in clinic. In order to improve the diagnostic and treatment level for COPD with integrated traditional Chinese and Western medicine, Chinese Medicine of internal Medicine Committee of World federation of Chinese Medicine Societies organized and established a multidisciplinary background working group, the document was formulated by referring to the formulating method and process of international guidelines in clinical practice, current evidence with the best quality, and characteristics of integrated traditional Chinese and Western medicine in treating COPD and weighing pros and cons of interventions, 13 recommendations were established, physicians can refer to this guideline to formulate individualized treatment plans in combination with the specific conditions of patients.

Citation： Internal Medicine Committee of World Federation of Chinese Medicine Societies Chinese Medicine Societies. Guideline of integrated Chinese and western medicine for diagnosis and treatment of chronic obstructive pulmonary disease. Chinese Journal of Evidence-Based Medicine, 2023, 23(10): 1117-1128. doi: 10.7507/1672-2531.202304016 Copy

1.	Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2022.
2.	李建生, 余学庆. 慢性阻塞性肺疾病中医分期分级防治策略. 中医杂志, 2019, 60(22): 1895-1899.
3.	World Health Organization. Who handbook for guideline development, 2nd ed.
4.	卢传坚, 杨克虎. 中西医结合诊疗指南制定手册. 北京: 人民卫生出版社, 2016.
5.	Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650): 924-926.
6.	Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med, 2017, 166(2): 128-132.
7.	Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol, 2007, 7: 10.
8.	Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 2011, 343: d5928.
9.	Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355: i4919.
10.	王小琴, 陈耀龙, 渠清源, 等. 病例系列研究方法学质量评价工具解读. 中国循证儿科杂志, 2015, 10(5): 381-385.
11.	Li JS. International clinical practice guideline of Chinese medicine: chronic obstructive pulmonary disease. World J TCM, 2020, 1(6): 39-50.
12.	世界中医药学会联合会. 国际中医临床实践指南慢性阻塞性肺疾病. 世界中医药, 2020, 15(7): 1084-1092.
13.	李建生, 张海龙, 王海峰, 等. 慢性阻塞性肺疾病证候演变特点临床调查. 中医杂志, 2017, 58(9): 772-776.
14.	李建生. 正虚积损为慢性阻塞性肺疾病的主要病机. 中华中医药杂志, 2011, 26(8): 1710-1713.
15.	李建生, 余学庆, 王明航, 等. 中医治疗慢性阻塞性肺疾病研究的策略与实践. 中华中医药杂志, 2012, 27(6): 1607-1614.
16.	Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med, 2014, 35(1): 71-86.
17.	Barnes PJ. COPD 2020: new directions needed. Am J Physiol Lung Cell Mol Physiol, 2020, 319(5): 884-886.
18.	王辰. 内科学. 北京: 人民卫生出版社, 2020.
19.	李建生, 王海峰. 基于慢性阻塞性肺疾病急性加重危险窗的袪邪扶正序贯辨证治疗策略. 中国中西医结合杂志, 2011, 31(9): 1276-1280.
20.	中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版). 中华结核和呼吸杂志, 2021, 44(3): 170-205.
21.	中华中医药学会内科分会肺系病专业委员会. 慢性阻塞性肺疾病中医证候诊断标准(2011版). 中医杂志, 2012, 53(2): 177-178.
22.	中国老年医学学会呼吸病学分会慢性阻塞性肺疾病学组. 中国老年慢性阻塞性肺疾病临床诊治实践指南. 中华结核和呼吸杂志, 2020, 43(2): 100-119.
23.	中华中医药学会. 慢性阻塞性肺疾病中医诊疗指南(2018修订版).
24.	Xiong C, Li Y, Zhuang G, et al. Clinical efficacy and safety of Chinese herbal medicine versus placebo for the treatment of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Complement Ther Med, 2021, 59: 102691.
25.	Zeng Y, Li Y, Wei H, et al. The effects and safety of Chinese oral herbal paste on stable chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med, 2020, 2020: 5867086.
26.	Chan KH, Tsoi YYS, McCall M. The effectiveness of traditional Chinese medicine (TCM) as an adjunct treatment on stable COPD patients: a systematic review and meta-analysis. Evid Based Complement Alternat Med, 2021, 2021: 5550332.
27.	李建生. 2011国家中医药行业专项项目课题—早期慢性阻塞性肺疾病稳定期中医治疗方案与转化应用研究. 2016.
28.	樊长征, 苗青, 樊茂蓉, 等. 慢性阻塞性肺疾病稳定期中医临床实践指南(征求意见稿). 中国中药杂志, 2020, 45(22): 5309-5322.
29.	邸家琪. 补肺益肾方治疗肺功能3、4级COPD疗效评价与急性加重预测模型的初步构建. 郑州: 河南中医药大学, 2022.
30.	Zhou Y, Zhong NS, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med, 2017, 377(10): 923-935.
31.	Ma J, Zheng J, Zhong N, et al. Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis, 2018, 13: 3107-3114.
32.	李建生. 国家十二五科技支撑计划课题—病证结合提高中医治疗慢性阻塞性肺疾病疗效研究. 2018.
33.	戴勇, 魏成功. 金水宝胶囊合家庭氧疗对慢性阻塞性肺疾病稳定期患者生存质量的影响. 中国实验方剂学杂志, 2010, 16(7): 206-209.
34.	喻敏, 王少飞, 王慧敏. 金水宝胶囊联合布地奈德福莫特罗治疗慢性阻塞性肺疾病稳定期的临床研究. 现代药物与临床, 2019, 34(9): 2645-2648.
35.	魏莉莉, 刘海. 慢性阻塞性肺疾病临床康复循证实践指南. 中国康复理论与实践, 2021, 27(1): 15-26.
36.	Li JS. Guidelines for Chinese medicine rehabilitation of chronic obstructive pulmonary disease. World J TCM, 2020, 6(3): 295-306.
37.	世界中医药学会联合会肺康复专业委员会. 慢性阻塞性肺疾病中医康复指南. 世界中医药, 2020, 15(23): 3710-3718.
38.	Li J, Zhang H, Ruan H, et al. Effects of Chinese herbal medicine on acute exacerbations of COPD: a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis, 2020, 15: 2901-2912.
39.	Gao Z, Jing J, Liu Y. Xiaoqinglong decoction (a traditional Chinese medicine) combined conventional treatment for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Medicine (Baltimore), 2020, 99(14): e19571.
40.	朱秀影, 谢惠芳, 韩海, 等. 3种中药注射剂治疗慢性阻塞性肺疾病急性加重期的网状Meta分析. 中国中药杂志, 2019, 44(10): 2179-2184.
41.	张海龙, 王明航, 李风雷, 等. 中医药辨证治疗急性加重期慢性阻塞性肺疾病随机对照试验疗效评价指标的系统评价. 中医学报, 2013, 28(6): 797-804.
42.	李东敏, 唐哲, 戴慧晖. 苏黄止咳胶囊对慢性阻塞性肺疾病患者肺功能的影响. 中国现代药物应用, 2020, 14(2): 132-134.
43.	任君清. 苏黄止咳胶囊对慢性阻塞性肺疾病急性加重期患者肺功能、血气分析及血清PCT、CRP的影响. 现代中西医结合杂志, 2019, 28(13): 1442-1445.
44.	邹艳丽, 徐辉, 周辉. 苏黄止咳胶囊辅助治疗老年慢性阻塞性肺疾病急性加重期的临床观察. 中医药导报, 2017, 23(19): 89-91.
45.	李艳彬, 夏友宏, 梁剑峰, 等. 疏风解毒胶囊治疗慢性阻塞性肺疾病急性加重期(痰热郁肺证)的临床观察. 中国中医急症, 2020, 29(11): 2025-2027.
46.	饶娟, 晏海飞, 周文博, 等. 疏风解毒胶囊治疗慢性阻塞性肺疾病急性加重期(痰热郁肺证)临床观察. 中国中医急症, 2020, 29(10): 1818-1820.
47.	田图磊, 唐超, 瞿香坤. 疏风解毒胶囊联合常规疗法治疗慢性阻塞性肺疾病急性加重期(痰热郁肺证)的临床观察. 中国中医急症, 2021, 30(1): 124-127.
48.	方明, 刘家昌. 复方抗流感中成药制剂院前干预慢性阻塞性肺疾病急性加重期临床观察. 中华中医药杂志, 2021, 36(2): 1168-1170.
49.	刘志刚, 孙宜芬, 孟红旗. 苏子降气汤治疗慢性阻塞性肺病急性加重疗效观察. 临床肺科杂志, 2016, 21(8): 1442-1445.
50.	Efficacy evaluation of supine daoyin in the treatment of acute exacerbation of chronic obstructive pulmonary disease: a multi-center, randomized controlled trial (on going).
51.	张东. 仰卧导引干预慢性阻塞性肺疾病急性加重期疗效的初步评价. 郑州: 河南中医药大学, 2022.
52.	谢芳, 吴永平, 刘磊, 等. 温针灸治疗慢性阻塞性肺病痰浊壅肺证: 随机对照研究. 中国针灸, 2019, 39(9): 918-922.
53.	谢洋, 王佳佳, 李宣霖, 等. 针刺治疗慢性阻塞性肺疾病急性加重期的临床研究文献分析. 中国老年学杂志, 2019, 39(13): 3151-3154.
54.	卢军仪, 赵丹, 孙义田, 等. 穴位贴敷辅助布地奈德治疗COPD急性加重期疗效及对其免疫功能和细胞因子表达的影响. 世界中西医结合杂志, 2021, 16(4): 700-704, 709.
55.	卢军仪, 赵丹, 孙义田, 等. 穴位贴敷组方治疗痰热郁肺型急性加重期慢性阻塞性肺疾病的临床观察. 世界中西医结合杂志, 2021, 16(7): 1324-1328.
56.	王芳, 王胜, 宋新, 等. “清肺散”穴位贴敷治疗痰热郁肺证慢性阻塞性肺疾病急性加重35例. 安徽中医药大学学报, 2020, 39(3): 36-39.
57.	王洋洋, 吕锦辉. 自拟益气化瘀方在AECOPD患者中辅助治疗对患者激素用量影响. 黑龙江中医药, 2017, 46(4): 6-8.
58.	Zhao K, Chen K, Huang Q, et al. Traditional Chinese medicine may reduce the dosage of systemic glucocorticoids in required patients with acute exacerbation of chronic obstructive pulmonary disease: study protocol for a randomized placebo-controlled trial. Medicine (Baltimore), 2020, 99(18): e20035.
59.	Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J, 2019, 53(5): 34.
60.	Di J, Li X, Xie Y, et al. Procalcitonin-guided antibiotic therapy in AECOPD patients: overview of systematic reviews. Clin Respir J, 2021, 15(6): 579-594.
61.	Litao G, Jingjing S, Yu L, et al. Risk factors for antibiotic-associated diarrhea in critically Ill patients. Med Sci Monit, 2018, 24: 5000-5007.
62.	郭利涛, 樊静群, 李萌, 等. ICU患者应用碳青霉烯类抗菌药物治疗时发生抗生素相关性腹泻的相关因素分析. 中华实用诊断与治疗杂志, 2019, 33(8): 823-825.
63.	李国生, 许光兰, 李娇, 等. 清金化痰汤联合西药治疗慢性阻塞性肺疾病急性加重期患者的临床效果. 中国医药, 2018, 13(7): 1012-1016.
64.	吴蔚, 王彬, 汪伟, 等. 清金化浊方对感染性慢性阻塞性肺疾病急性加重患者抗生素疗程的影响. 中医杂志, 2017, 58(20): 1764-1767.
65.	Jiansheng L, Haifeng W, Suyun L, et al. Effect of sequential treatment with TCM syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD risk window. Complement Ther Med, 2016, 29: 109-115.
66.	Effects of traditional Chinese medicine on AECOPD risk window patients: a multi-center, randomized, double-blind, controlled trial (on going).
67.	蒋艳丽, 王海峰, 李建生. 中医药治疗慢性阻塞性肺疾病急性加重期呼吸衰竭研究述评. 中医学报, 2012, 27(6): 670-672.
68.	李建生. 关于慢性呼吸衰竭中医诊断及辨证治疗标准的研究. 中医学报, 2010, 25(4): 627-629.
69.	李建生, 王明航, 余学庆, 等. 慢性阻塞性肺疾病呼吸衰竭中医证候分布规律的文献研究. 中医杂志, 2010, 51(1): 68-71.
70.	王海峰, 李建生, 王丁超, 等. 中医辨证配合西医治疗慢性阻塞性肺疾病急性加重呼吸衰竭52例临床观察. 中医杂志, 2013, 54(8): 664-667.
71.	温敏勇, 赵馥, 徐运升, 等. 健脾益胃化痰法对慢性阻塞性肺疾病急性加重期呼吸衰竭机械通气患者的免疫功能和脱机成功率的影响分析. 中华中医药学刊, 2018, 36(4): 920-922.
72.	肖磊, 马丽敏, 刘美秀. 自拟清肺化痰方联合无创通气、信必可都保治疗老年AECOPD伴呼吸衰竭的疗效研究. 中国中医急症, 2020, 29(10): 1784-1787.
73.	程茹, 张明华, 俞万钧. 通腑平喘汤对老年慢性阻塞性肺疾病合并呼吸衰竭的疗效及FVC、FEV1/FVC水平的影响. 中华中医药学刊, 2018, 36(7): 1653-1656.
74.	赵新爱, 金晓烨, 贺丽, 等. 益气涤痰通腑汤辅助治疗慢性阻塞性肺疾病合并呼吸衰竭患者100例临床观察. 中医杂志, 2014, 55(13): 1120-1122.
75.	钟恺立, 张宇. 大承气汤灌肠联合有创机械通气治疗慢性阻塞性肺疾病呼吸衰竭疗效观察. 中国中医急症, 2014, 23(1): 109-111.
76.	狐启贵, 刘良丽. 益气活血化痰法联合无创辅助通气治疗慢阻肺急性加重期呼吸衰竭. 中国实验方剂学杂志, 2013, 19(20): 303-306.
77.	李素云, 马利军, 吴其标. 益气活血化痰开窍法为主治疗慢性阻塞性肺疾病合并呼吸衰竭疗效观察. 中国中医急症, 2002, 11(1): 9-10.
78.	Yiqi Huoxue Huatan granule for reducing mortality in with COPD chronic respiratory failure (on going).
79.	Treatment of CRF with syndrome differentiation of TCM (on going).
80.	董政委, 樊官伟. 活血化瘀法治疗低氧型肺高压的Meta分析. 世界中西医结合杂志, 2021, 16(4): 617-622, 639.
81.	徐向前, 徐倍琪, 郭晓燕, 等. 加味川芎平喘合剂治疗慢性阻塞性肺疾病稳定期合并肺动脉高压的临床疗效观察. 中华中医药杂志, 2019, 34(7): 3338-3340.
82.	唐婷玉, 俞李羚, 陆晓玲, 等. 活血化瘀治疗对慢性阻塞性肺疾病伴高凝状态患者血管内皮功能的影响. 中华中医药学刊, 2015, 33(9): 2192-2194.
83.	王彬, 吴蔚, 汪伟, 等. 补肺化痰活血中药治疗慢性阻塞性肺疾病合并肺动脉高压临床观察. 中国中医药信息杂志, 2012, 19(7): 72-73.
84.	叶健铿, 蒙晓, 吴耀洲, 等. AECOPD患者住院直接经济负担影响因素分析及相关建议. 中国药房, 2022, 33(12): 1474-1478.
85.	李春盈, 杨振宇, 冯超. 中西医结合治疗慢性阻塞性肺疾病急性加重期临床观察. 四川中医, 2022, 40(6): 82-84.
86.	余学庆, 李建生, 李素云, 等. 两种慢性阻塞性肺疾病治疗方案的成本-效果分析. 辽宁中医杂志, 2006, 33(3): 294-295.

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2022.
2. 李建生, 余学庆. 慢性阻塞性肺疾病中医分期分级防治策略. 中医杂志, 2019, 60(22): 1895-1899.
3. World Health Organization. Who handbook for guideline development, 2nd ed.
4. 卢传坚, 杨克虎. 中西医结合诊疗指南制定手册. 北京: 人民卫生出版社, 2016.
5. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650): 924-926.
6. Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med, 2017, 166(2): 128-132.
7. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol, 2007, 7: 10.
8. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 2011, 343: d5928.
9. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355: i4919.
10. 王小琴, 陈耀龙, 渠清源, 等. 病例系列研究方法学质量评价工具解读. 中国循证儿科杂志, 2015, 10(5): 381-385.
11. Li JS. International clinical practice guideline of Chinese medicine: chronic obstructive pulmonary disease. World J TCM, 2020, 1(6): 39-50.
12. 世界中医药学会联合会. 国际中医临床实践指南慢性阻塞性肺疾病. 世界中医药, 2020, 15(7): 1084-1092.
13. 李建生, 张海龙, 王海峰, 等. 慢性阻塞性肺疾病证候演变特点临床调查. 中医杂志, 2017, 58(9): 772-776.
14. 李建生. 正虚积损为慢性阻塞性肺疾病的主要病机. 中华中医药杂志, 2011, 26(8): 1710-1713.
15. 李建生, 余学庆, 王明航, 等. 中医治疗慢性阻塞性肺疾病研究的策略与实践. 中华中医药杂志, 2012, 27(6): 1607-1614.
16. Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med, 2014, 35(1): 71-86.
17. Barnes PJ. COPD 2020: new directions needed. Am J Physiol Lung Cell Mol Physiol, 2020, 319(5): 884-886.
18. 王辰. 内科学. 北京: 人民卫生出版社, 2020.
19. 李建生, 王海峰. 基于慢性阻塞性肺疾病急性加重危险窗的袪邪扶正序贯辨证治疗策略. 中国中西医结合杂志, 2011, 31(9): 1276-1280.
20. 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版). 中华结核和呼吸杂志, 2021, 44(3): 170-205.
21. 中华中医药学会内科分会肺系病专业委员会. 慢性阻塞性肺疾病中医证候诊断标准(2011版). 中医杂志, 2012, 53(2): 177-178.
22. 中国老年医学学会呼吸病学分会慢性阻塞性肺疾病学组. 中国老年慢性阻塞性肺疾病临床诊治实践指南. 中华结核和呼吸杂志, 2020, 43(2): 100-119.
23. 中华中医药学会. 慢性阻塞性肺疾病中医诊疗指南(2018修订版).
24. Xiong C, Li Y, Zhuang G, et al. Clinical efficacy and safety of Chinese herbal medicine versus placebo for the treatment of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Complement Ther Med, 2021, 59: 102691.
25. Zeng Y, Li Y, Wei H, et al. The effects and safety of Chinese oral herbal paste on stable chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med, 2020, 2020: 5867086.
26. Chan KH, Tsoi YYS, McCall M. The effectiveness of traditional Chinese medicine (TCM) as an adjunct treatment on stable COPD patients: a systematic review and meta-analysis. Evid Based Complement Alternat Med, 2021, 2021: 5550332.
27. 李建生. 2011国家中医药行业专项项目课题—早期慢性阻塞性肺疾病稳定期中医治疗方案与转化应用研究. 2016.
28. 樊长征, 苗青, 樊茂蓉, 等. 慢性阻塞性肺疾病稳定期中医临床实践指南(征求意见稿). 中国中药杂志, 2020, 45(22): 5309-5322.
29. 邸家琪. 补肺益肾方治疗肺功能3、4级COPD疗效评价与急性加重预测模型的初步构建. 郑州: 河南中医药大学, 2022.
30. Zhou Y, Zhong NS, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med, 2017, 377(10): 923-935.
31. Ma J, Zheng J, Zhong N, et al. Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis, 2018, 13: 3107-3114.
32. 李建生. 国家十二五科技支撑计划课题—病证结合提高中医治疗慢性阻塞性肺疾病疗效研究. 2018.
33. 戴勇, 魏成功. 金水宝胶囊合家庭氧疗对慢性阻塞性肺疾病稳定期患者生存质量的影响. 中国实验方剂学杂志, 2010, 16(7): 206-209.
34. 喻敏, 王少飞, 王慧敏. 金水宝胶囊联合布地奈德福莫特罗治疗慢性阻塞性肺疾病稳定期的临床研究. 现代药物与临床, 2019, 34(9): 2645-2648.
35. 魏莉莉, 刘海. 慢性阻塞性肺疾病临床康复循证实践指南. 中国康复理论与实践, 2021, 27(1): 15-26.
36. Li JS. Guidelines for Chinese medicine rehabilitation of chronic obstructive pulmonary disease. World J TCM, 2020, 6(3): 295-306.
37. 世界中医药学会联合会肺康复专业委员会. 慢性阻塞性肺疾病中医康复指南. 世界中医药, 2020, 15(23): 3710-3718.
38. Li J, Zhang H, Ruan H, et al. Effects of Chinese herbal medicine on acute exacerbations of COPD: a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis, 2020, 15: 2901-2912.
39. Gao Z, Jing J, Liu Y. Xiaoqinglong decoction (a traditional Chinese medicine) combined conventional treatment for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Medicine (Baltimore), 2020, 99(14): e19571.
40. 朱秀影, 谢惠芳, 韩海, 等. 3种中药注射剂治疗慢性阻塞性肺疾病急性加重期的网状Meta分析. 中国中药杂志, 2019, 44(10): 2179-2184.
41. 张海龙, 王明航, 李风雷, 等. 中医药辨证治疗急性加重期慢性阻塞性肺疾病随机对照试验疗效评价指标的系统评价. 中医学报, 2013, 28(6): 797-804.
42. 李东敏, 唐哲, 戴慧晖. 苏黄止咳胶囊对慢性阻塞性肺疾病患者肺功能的影响. 中国现代药物应用, 2020, 14(2): 132-134.
43. 任君清. 苏黄止咳胶囊对慢性阻塞性肺疾病急性加重期患者肺功能、血气分析及血清PCT、CRP的影响. 现代中西医结合杂志, 2019, 28(13): 1442-1445.
44. 邹艳丽, 徐辉, 周辉. 苏黄止咳胶囊辅助治疗老年慢性阻塞性肺疾病急性加重期的临床观察. 中医药导报, 2017, 23(19): 89-91.
45. 李艳彬, 夏友宏, 梁剑峰, 等. 疏风解毒胶囊治疗慢性阻塞性肺疾病急性加重期(痰热郁肺证)的临床观察. 中国中医急症, 2020, 29(11): 2025-2027.
46. 饶娟, 晏海飞, 周文博, 等. 疏风解毒胶囊治疗慢性阻塞性肺疾病急性加重期(痰热郁肺证)临床观察. 中国中医急症, 2020, 29(10): 1818-1820.
47. 田图磊, 唐超, 瞿香坤. 疏风解毒胶囊联合常规疗法治疗慢性阻塞性肺疾病急性加重期(痰热郁肺证)的临床观察. 中国中医急症, 2021, 30(1): 124-127.
48. 方明, 刘家昌. 复方抗流感中成药制剂院前干预慢性阻塞性肺疾病急性加重期临床观察. 中华中医药杂志, 2021, 36(2): 1168-1170.
49. 刘志刚, 孙宜芬, 孟红旗. 苏子降气汤治疗慢性阻塞性肺病急性加重疗效观察. 临床肺科杂志, 2016, 21(8): 1442-1445.
50. Efficacy evaluation of supine daoyin in the treatment of acute exacerbation of chronic obstructive pulmonary disease: a multi-center, randomized controlled trial (on going).
51. 张东. 仰卧导引干预慢性阻塞性肺疾病急性加重期疗效的初步评价. 郑州: 河南中医药大学, 2022.
52. 谢芳, 吴永平, 刘磊, 等. 温针灸治疗慢性阻塞性肺病痰浊壅肺证: 随机对照研究. 中国针灸, 2019, 39(9): 918-922.
53. 谢洋, 王佳佳, 李宣霖, 等. 针刺治疗慢性阻塞性肺疾病急性加重期的临床研究文献分析. 中国老年学杂志, 2019, 39(13): 3151-3154.
54. 卢军仪, 赵丹, 孙义田, 等. 穴位贴敷辅助布地奈德治疗COPD急性加重期疗效及对其免疫功能和细胞因子表达的影响. 世界中西医结合杂志, 2021, 16(4): 700-704, 709.
55. 卢军仪, 赵丹, 孙义田, 等. 穴位贴敷组方治疗痰热郁肺型急性加重期慢性阻塞性肺疾病的临床观察. 世界中西医结合杂志, 2021, 16(7): 1324-1328.
56. 王芳, 王胜, 宋新, 等. “清肺散”穴位贴敷治疗痰热郁肺证慢性阻塞性肺疾病急性加重35例. 安徽中医药大学学报, 2020, 39(3): 36-39.
57. 王洋洋, 吕锦辉. 自拟益气化瘀方在AECOPD患者中辅助治疗对患者激素用量影响. 黑龙江中医药, 2017, 46(4): 6-8.
58. Zhao K, Chen K, Huang Q, et al. Traditional Chinese medicine may reduce the dosage of systemic glucocorticoids in required patients with acute exacerbation of chronic obstructive pulmonary disease: study protocol for a randomized placebo-controlled trial. Medicine (Baltimore), 2020, 99(18): e20035.
59. Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J, 2019, 53(5): 34.
60. Di J, Li X, Xie Y, et al. Procalcitonin-guided antibiotic therapy in AECOPD patients: overview of systematic reviews. Clin Respir J, 2021, 15(6): 579-594.
61. Litao G, Jingjing S, Yu L, et al. Risk factors for antibiotic-associated diarrhea in critically Ill patients. Med Sci Monit, 2018, 24: 5000-5007.
62. 郭利涛, 樊静群, 李萌, 等. ICU患者应用碳青霉烯类抗菌药物治疗时发生抗生素相关性腹泻的相关因素分析. 中华实用诊断与治疗杂志, 2019, 33(8): 823-825.
63. 李国生, 许光兰, 李娇, 等. 清金化痰汤联合西药治疗慢性阻塞性肺疾病急性加重期患者的临床效果. 中国医药, 2018, 13(7): 1012-1016.
64. 吴蔚, 王彬, 汪伟, 等. 清金化浊方对感染性慢性阻塞性肺疾病急性加重患者抗生素疗程的影响. 中医杂志, 2017, 58(20): 1764-1767.
65. Jiansheng L, Haifeng W, Suyun L, et al. Effect of sequential treatment with TCM syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD risk window. Complement Ther Med, 2016, 29: 109-115.
66. Effects of traditional Chinese medicine on AECOPD risk window patients: a multi-center, randomized, double-blind, controlled trial (on going).
67. 蒋艳丽, 王海峰, 李建生. 中医药治疗慢性阻塞性肺疾病急性加重期呼吸衰竭研究述评. 中医学报, 2012, 27(6): 670-672.
68. 李建生. 关于慢性呼吸衰竭中医诊断及辨证治疗标准的研究. 中医学报, 2010, 25(4): 627-629.
69. 李建生, 王明航, 余学庆, 等. 慢性阻塞性肺疾病呼吸衰竭中医证候分布规律的文献研究. 中医杂志, 2010, 51(1): 68-71.
70. 王海峰, 李建生, 王丁超, 等. 中医辨证配合西医治疗慢性阻塞性肺疾病急性加重呼吸衰竭52例临床观察. 中医杂志, 2013, 54(8): 664-667.
71. 温敏勇, 赵馥, 徐运升, 等. 健脾益胃化痰法对慢性阻塞性肺疾病急性加重期呼吸衰竭机械通气患者的免疫功能和脱机成功率的影响分析. 中华中医药学刊, 2018, 36(4): 920-922.
72. 肖磊, 马丽敏, 刘美秀. 自拟清肺化痰方联合无创通气、信必可都保治疗老年AECOPD伴呼吸衰竭的疗效研究. 中国中医急症, 2020, 29(10): 1784-1787.
73. 程茹, 张明华, 俞万钧. 通腑平喘汤对老年慢性阻塞性肺疾病合并呼吸衰竭的疗效及FVC、FEV1/FVC水平的影响. 中华中医药学刊, 2018, 36(7): 1653-1656.
74. 赵新爱, 金晓烨, 贺丽, 等. 益气涤痰通腑汤辅助治疗慢性阻塞性肺疾病合并呼吸衰竭患者100例临床观察. 中医杂志, 2014, 55(13): 1120-1122.
75. 钟恺立, 张宇. 大承气汤灌肠联合有创机械通气治疗慢性阻塞性肺疾病呼吸衰竭疗效观察. 中国中医急症, 2014, 23(1): 109-111.
76. 狐启贵, 刘良丽. 益气活血化痰法联合无创辅助通气治疗慢阻肺急性加重期呼吸衰竭. 中国实验方剂学杂志, 2013, 19(20): 303-306.
77. 李素云, 马利军, 吴其标. 益气活血化痰开窍法为主治疗慢性阻塞性肺疾病合并呼吸衰竭疗效观察. 中国中医急症, 2002, 11(1): 9-10.
78. Yiqi Huoxue Huatan granule for reducing mortality in with COPD chronic respiratory failure (on going).
79. Treatment of CRF with syndrome differentiation of TCM (on going).
80. 董政委, 樊官伟. 活血化瘀法治疗低氧型肺高压的Meta分析. 世界中西医结合杂志, 2021, 16(4): 617-622, 639.
81. 徐向前, 徐倍琪, 郭晓燕, 等. 加味川芎平喘合剂治疗慢性阻塞性肺疾病稳定期合并肺动脉高压的临床疗效观察. 中华中医药杂志, 2019, 34(7): 3338-3340.
82. 唐婷玉, 俞李羚, 陆晓玲, 等. 活血化瘀治疗对慢性阻塞性肺疾病伴高凝状态患者血管内皮功能的影响. 中华中医药学刊, 2015, 33(9): 2192-2194.
83. 王彬, 吴蔚, 汪伟, 等. 补肺化痰活血中药治疗慢性阻塞性肺疾病合并肺动脉高压临床观察. 中国中医药信息杂志, 2012, 19(7): 72-73.
84. 叶健铿, 蒙晓, 吴耀洲, 等. AECOPD患者住院直接经济负担影响因素分析及相关建议. 中国药房, 2022, 33(12): 1474-1478.
85. 李春盈, 杨振宇, 冯超. 中西医结合治疗慢性阻塞性肺疾病急性加重期临床观察. 四川中医, 2022, 40(6): 82-84.
86. 余学庆, 李建生, 李素云, 等. 两种慢性阻塞性肺疾病治疗方案的成本-效果分析. 辽宁中医杂志, 2006, 33(3): 294-295.

Next Article
Development and validation of a prognostic nomogram after hepatectomy for intrahepatic cholangiocarcinoma based on SEER database

Chinese Journal of Evidence-Based Medicine

Guideline of integrated Chinese and western medicine for diagnosis and treatment of chronic obstructive pulmonary disease

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content